[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,994,552
  • Shares Outstanding, K 105,720
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,629 M
  • EBITDA $ 4,173 M
  • 60-Month Beta 0.30
  • Price/Sales 4.58
  • Price/Cash Flow 14.81
  • Price/Book 2.09

Options Overview Details

View History
  • Implied Volatility 31.33% (+1.19%)
  • Historical Volatility 40.33%
  • IV Percentile 12%
  • IV Rank 22.44%
  • IV High 49.01% on 10/10/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 6) 15.10 (2.46%)
  • Put/Call Vol Ratio 0.93
  • Today's Volume 2,787
  • Volume Avg (30-Day) 1,916
  • Put/Call OI Ratio 1.05
  • Today's Open Interest 42,873
  • Open Int (30-Day) 42,968
  • Expected Range 599.68 to 629.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $8.40
  • Number of Estimates 7
  • High Estimate $11.13
  • Low Estimate $6.29
  • Prior Year $10.72
  • Growth Rate Est. (year over year) -21.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
609.77 +0.82%
on 05/29/26
730.59 -15.85%
on 05/13/26
-71.58 (-10.43%)
since 04/29/26
3-Month
609.77 +0.82%
on 05/29/26
794.77 -22.65%
on 03/03/26
-166.89 (-21.35%)
since 02/27/26
52-Week
476.49 +29.02%
on 06/05/25
821.11 -25.13%
on 01/09/26
+22.93 (+3.87%)
since 05/28/25

Most Recent Stories

More News
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

Inmazeb ® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically...

REGN : 614.78 (-1.08%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

NEW YORK , May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).  Such investors...

REGN : 614.78 (-1.08%)
Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink?

Regeneron Pharmaceuticals has underperformed the broader market over the past year, and analysts remain reasonably bullish about the stock’s long term prospects.

XLV : 149.47 (-0.93%)
$SPX : 7,580.06 (+0.22%)
REGN : 614.78 (-1.08%)
Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) Over Potential Securities Fraud Allegations

New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.")...

REGN : 614.78 (-1.08%)
Amylyx Stock: Why the Full Pipeline Story Matters

Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares

AMLX : 14.35 (+0.91%)
MRK : 118.72 (-0.98%)
REGN : 614.78 (-1.08%)
Stocks making big moves this week: Toll Brothers, Booz Allen Hamilton, Strategy, Regeneron, and Micron

Stocks making big moves this week: Toll Brothers, Booz Allen Hamilton, Strategy, Regeneron, and Micron

TOL : 138.54 (+0.29%)
MSTR : 159.09 (+4.91%)
MU : 971.00 (+5.14%)
BAH : 79.18 (-2.31%)
REGN : 614.78 (-1.08%)
Otarmeniâ„¢ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment...

REGN : 614.78 (-1.08%)
1 of Wall Street’s Favorite Stock with Solid Fundamentals and 2 We Question

1 of Wall Street’s Favorite Stock with Solid Fundamentals and 2 We Question

TWI : 7.22 (-0.69%)
REGN : 614.78 (-1.08%)
VMC : 282.92 (+2.23%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors...

REGN : 614.78 (-1.08%)
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Normalization of free light chains occurred by day 15 across all doses 100% of patients achieved a hematologic complete response (CR) at the highest tested dose Majority of patients with renal...

REGN : 614.78 (-1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 637.61
2nd Resistance Point 631.04
1st Resistance Point 622.91
Last Price 614.78
1st Support Level 608.21
2nd Support Level 601.64
3rd Support Level 593.51

See More

52-Week High 821.11
Fibonacci 61.8% 689.46
Fibonacci 50% 648.80
Last Price 614.78
Fibonacci 38.2% 608.13
52-Week Low 476.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.